Polymorphisms in genes such as BCL11A and HBS1L-MYB have been identified as key regulators of HbF production, offering potential targets for therapeutic modulation and personalized management of nephropathy in SCD patients. This evidence concerns the gene HBS1L and Schnyder corneal dystrophy.